重度三尖瓣反流患者经导管三尖瓣修复后的健康状况
T-TEER 组在 1 个月和 1 年时 KCCQ 总体症状评分较药物治疗组显著改善,1 年时存活且健康状况良好(KCCQ≥60 且较基线下降≤10 分)的比例更高。
要点
- T-TEER 较药物治疗显著改善 1 个月和 1 年健康状况,1 年组间 KCCQ 评分差 10.4 分。
- T-TEER 组 1 年存活且健康状况良好的比例为 74.8%,药物治疗组为 45.9%。
- 基线 KCCQ 评分越高,T-TEER 的健康状况获益越小。
核心结论
- 与单纯药物治疗相比,使用 TriClip 系统的 T-TEER 可为重度三尖瓣反流患者带来显著且持续的健康状况改善。
研究设计与样本
- TRILUMINATE Pivotal 随机对照试验,将重度三尖瓣反流患者随机分配至 T-TEER 组(n=175)或药物治疗组(n=175),采用 KCCQ 在基线及 1、6、12 个月评估健康状况。
主要发现
- T-TEER 组 1 个月时 KCCQ 总体症状评分较药物治疗组平均提高 9.4 分(95%CI:5.3-13.4)。
- T-TEER 组 1 年时 KCCQ 总体症状评分较药物治疗组平均提高 10.4 分(95%CI:6.3-14.6)。
- T-TEER 组 1 年时存活且健康状况良好(KCCQ 总体症状评分≥60 且较基线下降≤10 分)的比例为 74.8%,药物治疗组为 45.9%(P<0.001)。
- 需治疗人数(NNT)为 3.5。
- 交互分析显示,基线 KCCQ 总体症状评分越高,T-TEER 的健康状况获益越小(Pint<0.001)。
关键数值与推荐
- KCCQ 总体症状评分范围 0-100 分,分数越高健康状况越好。
- 存活且健康状况良好定义为 KCCQ 总体症状评分≥60 分且 1 年时较基线下降不超过 10 分。
临床怎么用
- 对于重度三尖瓣反流患者,T-TEER 可显著改善 1 年健康状况,且基线 KCCQ 评分较低者获益可能更大。
局限性
- 探索性分析提示 T-TEER 的健康状况获益大部分可由三尖瓣反流减少解释,且健康状况改善与 1 年死亡和心衰住院减少强相关,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal), tricuspid transcatheter edge-to-edge repair (T-TEER) reduced tricuspid regurgitation (TR) and improved health status compared with medical therapy alone with no benefit on heart failure hospitalizations or survival. OBJECTIVES: The purpose of this study was to better understand the health status benefits of T-TEER within the TRILUMINATE Pivotal trial. METHODS: TRILUMINATE randomized patients with severe TR to T-TEER (n = 175) or medical therapy (n = 175). Health status was assessed at baseline and at 1, 6, and 12 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) (range 0-100; higher = better), which was compared between treatment groups using mixed effects linear regression. Alive and well was defined as KCCQ overall summary score ≥60 and no decline from baseline of >10 points at 1 year. RESULTS: Compared with medical therapy, T-TEER significantly improved health status at 1 month (mean between-group difference in KCCQ overall summary score 9.4 points; 95% CI: 5.3-13.4 points), with a small additional improvement at 1 year (mean between-group difference 10.4 points; 95% CI: 6.3-14.6 points). T-TEER patients were more likely to be alive and well at 1 year (T-TEER vs medical therapy: 74.8% vs 45.9%; P < 0.001), with a number needed to treat of 3.5. Interaction analyses demonstrated that the benefit of T-TEER diminished as baseline KCCQ overall summary score increased (Pint < 0.001). Exploratory analyses suggested that much of the health status benefit of T-TEER could be explained by TR reduction and that improvement in health status after T-TEER was strongly correlated with reduced 1-year mortality and heart failure hospitalization. CONCLUSIONS: T-TEER with the TriClip system resulted in substantial and sustained health status improvement in patients with severe TR compared with medical therapy alone.
引用
- Arnold SV, Goates S, Sorajja P, et al. Health Status After Transcatheter Tricuspid-Valve Repair in Patients With Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2023. PMID: 37898329. doi:10.1016/j.jacc.2023.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。